Literature DB >> 8423341

Enhancement of natural killer activity by an antibody to CD44.

P H Tan1, E B Santos, H C Rossbach, B M Sandmaier.   

Abstract

In this study, we examined the in vitro effect of an anti-CD44 mAb, S5, on NK function using canine PBMC as effectors. S5 enhanced NK activity in a dose-dependent and rapid fashion as did IM7, another anti-CD44 mAb that recognizes a common epitope(s) on CD44. Other anti-CD44 mAb (Hermes-1 and S3) that recognize epitopes distinct from S5 and IM7 had a variable effect on NK activity. The activation of increased killing by S5 only occurred when NK-sensitive targets were used, suggesting that lymphokine-activated killer cells were not being induced. Antibody-dependent cell cytotoxicity was not the mechanism involved in the augmentation of NK activity, nor was it Fc receptor-dependent, inasmuch as S5 F(ab')2 was able to increase NK activity. F(ab') fragments of S5 were equivalent to intact S5 in their ability to stimulate NK activity, demonstrating that cross-linking of CD44 was not a necessary component of stimulation, and that nonspecific agglutination of target and effector cells was not occurring via the two F(ab) arms. The enhancement of NK function was monocyte-independent and mediated by radioresistant cells, indicating that the antibody enhanced NK cells directly. This finding would suggest that CD44 can direct a transmembrane signal for NK cell activation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423341

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Evaluation of posttransplant methotrexate to facilitate engraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model.

Authors:  Monica S Thakar; Erlinda B Santos; Theodore A Gooley; George Sale; Rainer Storb; Hans-Peter Kiem; Brenda M Sandmaier
Journal:  Transplantation       Date:  2010-07-15       Impact factor: 4.939

2.  Serum levels of the soluble adhesion molecules in patients with malignant melanoma.

Authors:  V Yasasever; F Tas; D Duranyildiz; H Camlica; S Kurul; N Dalay
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation.

Authors:  Yun Chen; Takahiro Fukuda; Monica S Thakar; Brian T Kornblit; Barry E Storer; Erlinda B Santos; Rainer Storb; Brenda M Sandmaier
Journal:  Cytotherapy       Date:  2011-08-17       Impact factor: 5.414

4.  CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells.

Authors:  M Kryworuckho; F Diaz-Mitoma; A Kumar
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 5.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

6.  The homing receptor CD44 is involved in the progression of precancerous gastric lesions in patients infected with Helicobacter pylori and in development of mucous metaplasia in mice.

Authors:  Jone Garay; M Blanca Piazuelo; Sumana Majumdar; Li Li; Jimena Trillo-Tinoco; Luis Del Valle; Barbara G Schneider; Alberto G Delgado; Keith T Wilson; Pelayo Correa; Jovanny Zabaleta
Journal:  Cancer Lett       Date:  2015-11-27       Impact factor: 8.679

Review 7.  The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy.

Authors:  Sourav Paul; Girdhari Lal
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

8.  Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity.

Authors:  M H Driessens; P J Stroeken; N F Rodriguez Erena; M A van der Valk; E A van Rijthoven; E Roos
Journal:  J Cell Biol       Date:  1995-12       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.